Vaxcyte Inc. (5VA)
Munich
Closed
Oct 23, 2026
Day's Range
56.5052 wk Range
34.60Overview - 5VA - Vaxcyte Inc.
Key Statistics
Valuation
Enterprise Value
4.51B
P/E (Trailing)
-11.01
PEG Ratio
-0.17
Price / Book
3.46
EV / EBITDA
-4.40
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-22.60%
Return on Equity
-36.51%
Ownership
Shares Outstanding
144.78M
Float
136.43M
Held by Insiders
0.48%
Held by Institutions
110.91%
Price stats
Beta
1.23
50-Day Avg
52.00
200-Day Avg
48.18
Market Cap - 5VA - Vaxcyte Inc.
Peers - 5VA - Vaxcyte Inc.
Peer Comparison
Compared with companies in Biotechnology listed on Munich.
- 5VAMunichVaxcyte Inc.9.68BMarket Cap+39.35%52-week change-11.01P/E (Trailing)0.00%Profit Margin
- 0QFMunichModerna Inc.78.99BMarket Cap+88.34%52-week change25.19P/E (Trailing)-141.42%Profit Margin
- 1AEAMunichargenx SE American Depositary Receipt45.08BMarket Cap+4.14%52-week change36.67P/E (Trailing)32.26%Profit Margin
- 30JMunichIDEAYA Biosciences Inc.3.20BMarket Cap+29.48%52-week change-26.37P/E (Trailing)-74.75%Profit Margin
- 0MEMunichTwist Bioscience Corporation3.10BMarket Cap+80.52%52-week change-107.77P/E (Trailing)50.72%Profit Margin
- 6461MunichIntech Biopharm Corporation2.66BMarket Cap-18.06%52-week change—P/E (Trailing)-103.17%Profit Margin
- 4DNMunichDenali Therapeutics Inc.2.55BMarket Cap+8.15%52-week change-5.39P/E (Trailing)0.00%Profit Margin
Profile Summary - 5VA - Vaxcyte Inc.
About
Vaxcyte Inc. is a clinical-stage vaccine company focused on developing next-generation vaccines for bacterial infectious diseases. The company uses its proprietary cell-free protein synthesis platform to design and produce optimized protein carriers and antigens, supporting the creation of conjugate and protein-based…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
